Thiopurine therapy, commonly used in autoimmune conditions, can be complicated by life-threatening leukopenia. This leukopenia is associated with genetic variation in TPMT (encoding thiopurine S-methyltransferase). Despite a lower frequency of TPMT mutations in Asians, the incidence of thiopurine-induced leukopenia is higher in Asians than in individuals of European descent. Here we performed an Immunochip-based 2-stage association study in 978 Korean subjects with Crohn's disease treated with thiopurines. We identified a nonsynonymous SNP in NUDT15 (encoding p.Arg139Cys) that was strongly associated with thiopurineinduced early leukopenia (odds ratio (OR) = 35.6; P combined = 4.88 × 10 −94 ). In Koreans, this variant demonstrated sensitivity and specificity of 89.4% and 93.2%, respectively, for thiopurine-induced early leukopenia (in comparison to 12.1% and 97.6% for TPMT variants). Although rare, this SNP was also strongly associated with thiopurine-induced leukopenia in subjects with inflammatory bowel disease of European descent (OR = 9.50; P = 4.64 × 10 −4 ). Thus, NUDT15 is a pharmacogenetic determinant for thiopurine-induced leukopenia in diverse populations.
Azathioprine (AZA) and its close analog 6-mercaptopurine (6-MP) are thiopurines widely used in the treatment of patients with cancers, organ transplantation, and autoimmune or inflammatory diseases, including inflammatory bowel diseases (IBD) 1, 2 . However, thiopurineassociated leukopenia is a substantial hazard that occurs in up to 5% of individuals with IBD of European descent [3] [4] [5] . The association between thiopurine-induced leukopenia and TPMT mutations is well established, and TPMT testing before thiopurine exposure is recommended by the US Food and Drug Administration (FDA). However, only about a quarter of individuals with IBD who have thiopurineassociated leukopenia carry a TPMT mutation, suggesting the existence of additional factors and also questioning the usefulness of pretesting for TPMT status in this situation [6] [7] [8] . Interestingly, although the frequency of TPMT mutations is lower in Asians than in individuals of European descent (~3% versus ~10%) [9] [10] [11] [12] [13] , the frequency at which thiopurine-induced leukopenia occurs in Asians is considerably higher 11, 12, 14 . Thiopurine-associated leukopenia (defined by a white blood cell (WBC) count of <3,000 cells/mm 3 ) was observed in 31.2% and 39.6% of Korean individuals with Crohn's disease at median AZA doses of 1.34 and 1.80 mg/kg/d, respectively 11, 14 . We therefore conducted an association analysis in a single-center Korean population with Crohn's disease to identify additional genetic variation associated with thiopurine-induced leukopenia. The workflow of the study is shown in Supplementary Figure 1 . In total, 66 of 978 eligible subjects developed leukopenia within 8 weeks of commencing thiopurine therapy (defined as early leukopenia cases 15 ). A further 280 experienced leukopenia after the first 8 weeks (defined as late leukopenia cases 15 ), and 632 did not experience leukopenia, despite exposure to ≥1 mg/kg/d AZA for ≥8 weeks (defined as controls) (Supplementary Table 1) .
Using the Immunochip (Illumina), we conducted a discovery association analysis of 95,405 genotyped SNPs in 33 cases with early leukopenia and 307 controls without leukopenia (Supplementary Fig. 1 ) that were randomly selected from the whole cohort of 978 participating subjects. An excess of low P values was observed at the tail of the quantile-quantile distribution (Supplementary Fig. 2 ), but there was no evidence of inflation due to population stratification (λ GC = 1.039). We observed four associations with leukopenia at P < 1 × 10 −5 at rs9843344 (3p25.1, FBLN2), rs1986731 (6p22.3, the CMAHP pseudogene), rs2945770 (8q24.22, ST3GAL1) and rs17109616 (14q31.1, NRXN3) (Supplementary Fig. 3 ). In addition, we observed suggestive association at TPMT (rs1142345, TPMT*3C) (OR = 7.11; P = 1.61 × 10 −4 ). Aiming to improve the coverage of genetic variants, we also performed the discovery analysis for 436,011 imputed SNPs and found 4 additional loci with association P < 1 × 10 −5 (1q32, 8q22, 13q14 and 14q31) (Supplementary Fig. 3 ). Only the SUCLA2-NUDT15-MED4 region at 13q14 showed multiple signals achieving genome-wide significance (P < 5 × 10 −8 ) (rs79076357, rs1168552132, 1 0 1 8 VOLUME 46 | NUMBER 9 | SEPTEMBER 2014 Nature GeNetics l e t t e r s rs142829497 and rs73481212), with the most significant association seen at rs142829497 (OR = 24.2; P = 2.36 × 10 −23 ).
One SNP from each of the eight loci showing association at P < 1 × 10 −5 , as well as rs116855232 in NUDT15, which leads to an amino acid substitution (basic arginine to polar cysteine) at position 139 of the protein, and rs1142345 within TPMT, were selected for replication in an additional 33 independent cases with early leukopenia and 325 controls. The assay for SNP rs142829497 failed, and, consequently, we instead analyzed rs73481212 (in complete linkage disequilibrium (LD) with rs142829497; r 2 = 1.00). Two SNPs within the SUCLA2-NUDT15-MED4 region at 13q14 were replicated, with associations achieving genome-wide significance (Supplementary Table 2) . A nonsynonymous SNP, rs116855232 (encoding p.Arg139Cys), showed the most significant and strongest association with early leukopenia in the combined analysis of the discovery (Immunochip) and replication samples (OR = 35.6; P combined = 4.88 × 10 −94 ) ( Table 1) . The other SNP, rs73481212, was in strong LD with rs116855232 (encoding p.Arg139Cys) (r 2 = 0.93). The TPMT*3C allele (rs1142345) also showed consistent association with early leukopenia in the replication sample (P < 0.05) but not at a genome-wide significant level in the combined analysis (P combined = 2.95 × 10 −5 ) (Supplementary Table 2 ).
As rs116855232 is within an LD region of ~185 kb in length that includes SUCLA2, NUDT15 and MED4, we searched for additional nonsynonymous SNPs using exome sequencing data from 59 Koreans (S.H. Oh, J.B., K.M. Kim, H.C. & Y.J. Lee et al., unpublished data). We identified two additional nonsynonymous SNPs, rs7320366 in SUCLA2 and rs186364861 in NUDT15, that were in moderate or low LD with rs116855232 (r 2 = 0.33 and 0, respectively). Only rs7320366 showed significant albeit more modest association with leukopenia (OR = 5.03; P combined = 3.55 × 10 −20 ) (Supplementary Table 3 ). Subsequent conditional logistic regression analysis indicated that the association of rs7320366 in SUCLA2 was completely abolished by conditioning on the association effect at rs116855232 in NUDT15, but the association at rs116855232 remained highly significant after conditioning on rs7320366 ( Fig. 1 and Supplementary Fig. 4 ).
Next, we tested for association with cases of late leukopenia and confirmed the effect of the NUDT15 variant encoding p.Arg139Cys in this population as well (OR = 5.29; P = 5.77 × 10 −21 ) (Supplementary Table 4) . Finally, using the same criteria for leukopenia as used in the Korean population, we found that the NUDT15 allele encoding p.Arg139Cys (overall allele frequency in individuals of European descent of ~0.004) was significantly associated with thiopurine-associated leukopenia in a US IBD cohort of 1,188 subjects with wild-type TPMT (allele frequency of 2.74% in leukopenia cases versus 0.31% in thiopurine-treated IBD cases without leukopenia; OR = 9.50; P = 4.64 × 10 −4 ).
Combining the discovery and replication Korean samples, we found that the NUDT15 allele encoding p.Arg139Cys was present in 89.4% (59/66) of the early leukopenia cases but was present in only 6.8% (43/632) of the controls (Supplementary Table 5 ), suggesting that the presence of this NUDT15 allele had a sensitivity of 89.4% (59/66) and specificity of 93.2% (589/632) for early leukopenia, with an area under the curve (AUC) value of 0.92 ( Supplementary Fig. 5 and Supplementary Table 5 ). Assuming a prevalence of 7% for early leukopenia in the Korean population (66/978), 16 cases would need to be tested to avoid 1 case of early leukopenia. Subjects carrying one copy of the NUDT15 risk allele had 88 times higher risk (heterozygous OR) for developing thiopurine-induced early leukopenia than non-carriers (Supplementary Table 5) , and no controls were homozygous for the NUDT15 risk allele. We also estimated the absolute risk of leukopenia for the different NUDT15 genotypes (Supplementary Table 6 ). In addition, as the number of copies of the NUDT15 risk allele increased, the dose of thiopurines at which leukopenia occurred decreased, the interval from the onset of thiopurine therapy to the development of leukopenia decreased and the grade of the observed leukopenia increased ( Table 2) . Together, these data suggest a gene-dose and JPT (Japanese in Tokyo, Japan) samples are plotted to reflect local LD structure. Plots were generated using LocusZoom.
l e t t e r s effect of the NUDT15 risk allele in the development of thiopurineassociated leukopenia. In contrast, TPMT variants showed only moderate association with early leukopenia (Supplementary Table 7) . In this study, we found TPMT mutations in only 3.8% (13/346) of Korean Crohn's disease cases with thiopurine-associated leukopenia, in keeping with published data [10] [11] [12] 16 and at much lower frequency than the ~25% reported in IBD cases of European descent 6, 7 .
Moreover, if we excluded 9 cases with both the TPMT*3C and NUDT15 risk alleles from the analysis, only 1.2% (4/346) of Korean Crohn's disease cases who experienced leukopenia during thiopurine therapy had TPMT mutations. These results suggest that TPMT genotyping before initiating thiopurine therapy is of limited use in Asians. However, the current clinical practice in Korea is to commence treatment with thiopurines at a low dose and slowly titrate the dose according to response to minimize adverse events. This practice may have led to an underestimation of the effects for both TPMT and NUDT15 variants. The NUDT15 risk allele encoding p.Arg139Cys is much more common in Asians than in individuals of European descent, with reported allele frequencies of 10.4% in Koreans, 7% in Japanese, 13% in Chinese and 2% in an admixed American population. This risk allele is present but at a very low frequency in individuals of European descent; nevertheless, individuals of European descent carrying the NUDT15 risk allele are also at significant risk of leukopenia during thiopurine therapy. NUDT15 (nucleoside diphosphate-linked moiety X-type motif 15) is a 164-amino-acid protein that belongs to the nudix hydrolase enzyme family, whose members are capable of hydrolyzing compounds with the general structure of a nucleoside diphosphate linked to another moiety, X. Although its substrate in vivo remains unclear, NUDT15 can degrade both 8-oxo-dGTP and 8-oxo-dGDP in vitro, suggesting that it might remove an oxidatively damaged form of guanine (7,8-dihydro-8-oxoguanine) from DNA and the nucleotide pool, thereby preventing misincorporation of 8-oxo-dGTP into DNA and preventing A:T to C:G transversions 17 . To investigate the functional role of the coding variant of NUDT15 (p.Arg139Cys) in the thiopurineinduced cytotoxicity effect, we measured the sensitivity of Jurkat cells to 6-MP after they were transfected with wild-type or mutant NUDT15 construct. After treatment with 7.5 µM 6-MP for 24 h, the number of viable Jurkat cells transfected with mutant NUDT15 construct was lower in comparison to the number of control cells transfected with wild-type construct (P = 0.00012; Supplementary Fig. 6 ). The levels of the apoptosis marker surface Annexin V were also significantly increased in mutant-transfected cells compared to those transfected with wild-type construct (P = 0.018; Supplementary Fig. 6 ), supporting a role for mutant NUDT15 in thiopurine-induced cytotoxicity. As Jurkat cells carry wild-type TPMT and NUDT15, it appears that the mutant NUDT15 has a dominant role in sensitivity to 6-MP.
In summary, we have identified and replicated a variant associated with substantially elevated risk of thiopurine-associated leukopenia in diverse populations. Our findings explain, in part, the higher prevalence of this phenomenon in Asians despite a lower prevalence of TPMT mutations. Our unbiased approach identified a nonsynonymous and potentially damaging polymorphism in a gene involved in purine metabolism that demonstrates clinical usefulness for anticipating patients at risk of this potentially life-threatening condition. Our findings have implications beyond IBD, as thiopurines are used in a number of oncological and immune-based conditions, as well as beyond the Korean population, given the allele frequency of this polymorphism in other Asian populations as well as the increased diversity of populations in regions such as North America and Europe. Future studies to explore the precise mechanism by which the NUDT15 p.Arg139Cys variant influences thiopurine-induced leukopenia and to identify additional genetic susceptibility loci for thiopurine-induced leukopenia within this pathway are warranted. 
